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Introduction
Apoptosis or programmed cell death is the major
genetically regulated process of cell self-destruction.
Apoptosis plays an essential role by controlling the
number of cells during maturation and allows elimi-
nation of damaged or neoplastically transformed
cells.  Apoptosis occurs via a mitochondria-depend-
ent or -independent pathway.  The former involves
enzymes called caspases, which if activated lead to
cytoskeleton disintegration, chromatin fragmentation
and formation of apoptotic bodies. On the other hand,
caspase activation depends on the action of other pro-
teins of the Bcl-2 family, including both caspase-acti-
vating enzymes (Bax, Bak, Bok, Bcl-xs, Bad, Bid,
Bik, Bim, BMF, HRK, NOXA, BBC3) and caspase-
inhibiting proteins (Bcl-2, Bcl-xL, Bcl-lw, Bfl-1,
Mcl-1). The balance between these groups of proteins
determines the occurrence of apoptosis [1,2]. Bax is
a pro-apoptotic protein belonging to the Bcl-2 family
and containing BH1 and BH2 domains as well as
BH3 domain through which it can form heterodimers
with Bcl-2 and Bcl-xL proteins. In normal cells, Bax
protein is located in the cytoplasm, whereas after
apoptosis initiation, Bax passes to membranes of cell
organelles, particularly to the mitochondrial mem-
brane. It has been proved that Bax overexpression
induces apoptosis in lung cancer [3]. It has been also
observed that reduced Bax expression is associated
with shorter survival in colorectal cancer patients [4].
Antagonistic to Bax is the anti-apoptotic protein Bcl-
xL, located on the surface of the mitochondrial mem-
brane and in the endoplasmic reticulum membrane.
Bcl-xL, built up of four domains  (BH1-BH4), plays
an important role in the inhibition of cytochrome c
release through binding to Bax and Bak proteins. It is
also involved in the neoplastic process. According to
numerous studies, Bcl-xL overexpression contributes
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to carcinogenesis by protecting tumor cells from
death  [4,5].
Apart from being involved in proliferation, the epi-
dermal growth factor (EGF) may also regulate apopto-
sis through its inhibition [1]. EGF is a single polypep-
tide, built up of 53 amino acids, that plays an essential
role in intercellular interactions.  Cooperation between
EGF of one cell and the receptor (EGFR) on the adja-
cent cell results in some biological effects, e.g. migra-
tion, growth or morphological changes in the cell. EGF
stimulates growth or exerts a trophic effect in many tis-
sues, including the pancreas and fibroblasts, and plays a
major role in proliferation, differentiation and matura-
tion of the embryonic intestine [6,7]. However, EGF and
EGFR, apart from being involved in normal develop-
ment, take part in neoplastic transformation. Increased
EGF and EGFR expressions have been observed in var-
ious malignancies, including carcinoma of the pancreas
[8], stomach [9], liver [10], and also brain tumors [11].
Literature widely describes neoplastic HER-2/neu
(cerbB-2) oncogene, which codes the trans-membrane
glycoprotein, closely related to EGFR. Overexpression
of c-erbB-2 has been found in carcinoma of the breast
[12], lungs [13] and stomach [14].
The study objective was the immunohistochemi-
cal assessment of the expressions of the apoptosis-
regulating proteins Bcl-xL and Bax as well as epider-
mal growth factor proteins EGF, EGFR c-erbB-2 in
pancreatic ductal carcinoma in correlation with cho-
sen anatomo-clinical parameters. 
Materials and methods
Tissue samples. The study group consisted of 29 patients, with
pancreatic ductal adenocarcinoma, who were operated on in the
Surgical Ward of the J. Œniadecki Hospital in Bia³ystok. Sec-
tions, 5 µm thick, were cut from paraffin blocks and stained with
hematoxylin and eosin (H+E). The routine histopathological
assessment of the sections referred to the histological type,
malignancy grade (G), clinico-pathological pTN status, regional
lymph node involvement and presence of distant metastases.
Immunohistochemistry. The protein expression was evaluated
by immunohistochemical reaction using antibodies for Bax
(Bax, P-19, sc-526-G, Santa Cruz Biotechnology), Bcl-xL (Bcl-
xL, N-19, sc-492-G, Santa Cruz Biotechnology), EGF (EGF-
Sigma, clone EGF-10; Sigma-Aldrich, Poland), EGFR (Clone:
H11, DAKO, Poland), c-erbB-2 (NCL-c-erbB-2-316, Novocas-
tra, Poland). A standard labeled streptavidin biotin (LSAB)
method protocol, described by DAKO (LSAB+HRP Kit,
DAKO) was used. The reaction products were visualized with
diaminobenzidine DAB (DAKO/S3000/Poland). A semiquanti-
tative method was used to evaluate EGF, EGFR, c-erbB-2
expression, which was defined as positive (reaction present in
>30% of tumor cells) or negative (lack of reaction or reaction
present in <30% of cells). The reaction to Bax and Bcl-xL was
evaluated according to the following criteria: 1-negative or weak
(lack of reaction or reaction present in <5% cells), 2-moderate
(reaction present in 6-30% of cells) and 3-strong (reaction pres-
ent in >30% of cells).
Statistical analysis. The percentage of the reaction-positive cells
was calculated in 500 neoplastic cells in each study sample at 400×
magnification. Spearman's correlation coefficient and χ2 test were
used for statistical analysis. A p-value of <0.05 was considered sta-
tistically significant. 
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Table 1. Immunohistochemical expressions of EGF, EGFR, c-erbB-2, Bcl-xL, Bax  in colorectal carcinomas in association with chosen
anatomo-clinical parameters. P<0.05 was considered statistically significant (marked bold).
Results
The study group included 6 women and 23 men aged
41-74 years. No expression of epidermal growth factor
was found in normal pancreas, whereas the expres-
sions of EGF, EGFR and c-erbB-2 in pancreatic ductal
carcinoma were elevated. In normal pancreas, the
expressions of the apoptosis-regulating proteins (Bax
and Bcl-xL) were found to be low in the cytoplasm,
whereas in ductal pancreatic cancer they were either
low, moderate or high. Statistical analysis revealed no
correlation of patients' age, tumor histological type and
malignancy grade with the expressions of EGF, EGFR,
c-erbB-2, Bax and Bcl-xL. Statistically significant
relationship was found between EGF expression and
patients' gender (p=0.034). A relationship was also
observed between lymph node involvement and the
expressions of EGF, EGFR, Bax and Bcl-xL (p=0.001,
p=0.001, p=0.008, p=0.012, respectively). The expres-
sions of EGF and EGFR were also found to correlate
with the presence of distant metastases (p=0.002,
p=0.008, respectively) (Table 1). Moreover, a statisti-
cally significant correlation was revealed between the
expression of EGF and Bax (p=0.041) and between c-
erbB-2 and Bcl-xL (p=0.030) (Table 2).
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Fig. 1. Immunohistochemical staining. Pancreatic duct carcinoma tissue
shows cytoplasmic reaction for EGF (A), EGFR (B), Bax (C), Bcl-xL
(D) and membrane reaction for c-erbB-2 (E).
Discussion
Processes of cell growth, proliferation and differentia-
tion as well as programmed death are regulated by var-
ious factors. Disturbances in these processes lead to
the growth of neoplastic cells, their uncontrolled pro-
liferation, aggressiveness and metastasizing to other
tissues.  We found a correlation of EGF and EGFR
expressions with anatomo-clinical parameters, such as
lymph node involvement. Moreover, increased expres-
sions of EGF and EGFR were found to correlate with
the presence of distant metastases. Thus, these proteins
play a role in spread of ductal pancreatic cancer. Sim-
ilar results have been reported by Yamanaka [15], who
found EGF, EGFR and c-erbB-2 to correlate consider-
ably with metastases to adjacent tissues. Also Zhang et
al. have demonstrated that EGFR expression can help
in the assessment of malignancy, progression and
metastasizing of ductal pancreatic cancer [16]. In our
study, enhanced expressions of Bax and Bcl-xL corre-
late considerably with the presence of lymph node
involvement. However, little is still known about the
effect of apoptosis-regulating proteins (Bax and Bcl-
xL) on metastasis formation. Ghaneh et al. [17] have
presented an overall comparison of the role of these
proteins in survival rate of patients with ductal pancre-
atic cancer. The expression of the apoptosis-stimulat-
ing Bax is associated with a considerably longer sur-
vival in patients with ductal pancreatic cancer, where-
as the expression of the apoptosis-inhibiting Bcl-xL is
related to their shorter survival. Thus, the coefficient
between the anti-apoptotic Bcl-xL and pro-apoptotic
Bax may play a key role in determination of survival
of neoplastic cells. More accurate studies in this field
might determine whether this coefficient can be a good
diagnostic marker in ductal pancreatic cancer.
Moreover, in our study, EGF correlated with Bax
expression, whereas c-erbB-2 with Bcl-xL expression.
The results indicate that the epidermal growth factor
proteins are related to the apoptosis-regulating pro-
teins. The epidermal growth factor family receptors
are trans-membrane proteins, with the intracellular
tyrosine kinase domain. Ligand-induced receptor stim-
ulation (EGF) causes activation of tyrosine kinase,
thus initiating a cascade of intracellular signaling
processes terminated by various biochemical changes
such as transcription, differentiation or stimulation of
cellular proliferation. Moreover, the activated tyrosine
kinase induces a number of transformations via
phospatidylinositol 3 kinase (AKT pathway). Phos-
phorylation and activation of the AKT cascade leads to
the inhibition of pro-apoptotic proteins  (e.g. Bax, Bak,
Bad) and hence to apoptosis suppression [1,18]. Thus,
as revealed in our study, increased expression of EGF
protein in ductal pancreatic cancer inhibits the action
of pro-apoptotic Bax protein. Neoplastic cells prolifer-
ate freely and do not undergo apoptosis, which leads to
cancer growth and adaptation to new locations. Also
the expression of c-erbB-2 receptor has been found to
correlate statistically significantly with the expression
of Bcl-xL; however, these correlations have not been
yet reported and require further investigations. Thus,
there is a relationship of growth factors with the apop-
tosis-regulating proteins and with their involvement in
cancer progression via metastasizing. There is a search
for EGFR inhibitor that would inhibit AKT pathway
activation; apoptosis would not be suppressed, making
neoplastically transformed cells die [18]. This would
allow implementation of therapy that would inhibit
further progression of ductal pancreatic cancer and
prolong patients' survival. 
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